PIK3CA and renal cell carcinoma: Proof of principle for the clinical potential to inhibit the PI3K/AKT pathway in human neoplasms was provided by the successful development of rapamycin-derivatives in the treatment of advanced renal cell carcinoma (RCC), where temsirolimus provides a significant overall survival benefit [21].